Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Targeted Search
Clinical Trials Search Results
Query: "AREA[SponsorSearch](Elan Pharmaceuticals)"
Count: 41
Selected: 0
| NCT ID | Title |
|---|
| NCT01318421 | A Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis | ||
| NCT01144351 | A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis | ||
| NCT00076544 | Ziconotide Effectiveness and Safety Trial in Patients With Chronic Severe Pain | ||
| NCT00055484 | A Study to Measure the Safety and Effectiveness of Zonisamide in Subjects With Migraine Headache | ||
| NCT00047749 | Prialt (Ziconotide) In Severe Chronic Pain | ||
| NCT00047580 | Comparison of Safety and Efficacy of Tizanidine Hydrochloride Capsules Versus Zanaflex® (Tizanidine Hydrochloride Tablets) Taken While in the Fed State (Just After a Meal) and in the Fasted State (Before a Meal) in Patients With Moderate to Severe Spasticity. | ||
| NCT00047567 | Open-label Adjunctive Zonisamide for Bipolar Disorder | ||
| NCT01791725 | A 4-Week Safety Study of Oral ELND005 in Young Adults With Down Syndrome Without Dementia | ||
| NCT01766336 | A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease | ||
| NCT01735630 | Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease | ||
| NCT01674010 | Safety and Efficacy Study of ELND005 as an Adjunctive Maintenance Treatment in Bipolar I Disorder | ||
| NCT01211665 | Corticosteroids for Immune Reconstitution Inflammatory Syndrome (IRIS) | ||
| NCT01071083 | Treatment Interruption of Natalizumab | ||
| NCT01058005 | Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis | ||
| NCT00871780 | A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients | ||
| NCT00831649 | A Phase II, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of Intravenous Natalizumab in Subjects With Rheumatoid Arthritis Who Have Previously Participated in Study ELN100226-RA201 | ||
| NCT00801125 | Study of Tysabri (Natalizumab) in Patients Who Failed Anti-TNF-α Therapy | ||
| NCT00746941 | Study to Explore the Effect of Mefloquine in Participants With Progressive Multifocal Leukoencephalopathy (PML) | ||
| NCT00744679 | A Pharmacokinetic (PK) Study of Natalizumab (Tysabri) at Steady State | ||
| NCT00618267 | ATP Expression in Lymphocytes of MS Patients by Means of "ImmuKnow®" Assay. | ||
| NCT00559702 | Safety Study of Natalizumab to Treat Multiple Sclerosis (MS) | ||
| NCT00516893 | Natalizumab High Titer Immunogenicity and Safety | ||
| NCT00472992 | Pregnancy Exposure Registry for Tysabri® | ||
| NCT00464074 | Evaluation of Natalizumab for thE Relief of MS Associated FatiGue | ||
| NCT00358202 | Cefepime vs. Ceftriaxone to Treat Nursing Home-Acquired Pneumonia | ||
| NCT00306592 | Natalizumab Re-Initiation of Dosing | ||
| NCT00280956 | Open Label Natalizumab Safety Extension Study for Subjects With Crohn's Disease | ||
| NCT00238641 | "DOES MYOBLOC™ IMPROVE FUNCTIONAL HAND USE IN YOUNG CHILDREN WITH A HYPERTONIC UPPER EXTREMITY?" | ||
| NCT00177736 | Pharmacodynamic Parameters of Two Different Doses of Cefepime | ||
| NCT00097760 | Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple Sclerosis | ||
| NCT00083759 | Natalizumab in the Treatment of Rheumatoid Arthritis in Subjects Receiving Methotrexate | ||
| NCT00078611 | A Clinical Trial of Natalizumab in Individuals With Moderately to Severely Active Crohn's Disease | ||
| NCT00055536 | Safety and Efficacy of Natalizumab in Combination With Remicade in the Treatment of Crohn's Disease | ||
| NCT00055367 | Safety, Tolerability and Effectiveness of Natalizumab in Adolescents With Active Crohn's Disease | ||
| NCT00032799 | Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease | ||
| NCT00032786 | Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease | ||
| NCT00030966 | Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis | ||
| NCT00027300 | Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis | ||
| NCT00035945 | ISIS 14803-CS2, Treatment With ISIS 14803, Administered IV in Patients With Chronic Hepatitis C Virus Infections | ||
| NCT01626248 | Analysis of Lymphocyte Cell Surface Adhesion Marker Expression in Natalizumab Population With Active Control | ||
| NCT01070823 | JC-Virus (JCV) Antibody Program |
